Seth R. Blacksburg, MD, MBA

Seth R. Blacksburg, MD, MBA

[types usermeta='affiliation' user_is_author='true'][/types]

[types usermeta='location' user_is_author='true'][/types]

Dr. Seth Blacksburg is Board Certified in Radiation Oncology and is the Associate Director of Radiation Oncology at NYU Winthrop Hospital and the Medical Director of the NYU Winthrop NYCyberKnife center in Manhattan. He earned his undergraduate degree from Tufts University, where he graduated Summa Cum Laude and with highest thesis honors. He pursued his medical degree from Duke University School of Medicine, where he also received his Masters in Business Administration with a concentration in Health Sector Management from the Duke University Fuqua School of Business. Dr. Blacksburg pursued research with the CEO and CIO of Duke University involving novel medical informatics applications. Dr. Blacksburg’s post-graduate training includes an internship in internal medicine at New York University and a residency at the Icahn School of Medicine at Mount Sinai, where he served as Chief Resident in Radiation Oncology for two years. Dr. Blacksburg continued on as faculty at Mount Sinai, where he was the first radiation oncologist selected into the Greater New York Hospital Association/United Hospital Fund Clinical Quality Fellowship. He has an expertise in the treatment of genitourinary, gastrointestinal, and central nervous system tumors using innovative radiation techniques such as brachytherapy, image guided radiation therapy (IGRT), stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT). Dr. Blacksburg is a member of several professional societies and is a frequent national lecturer.

Articles by Seth R. Blacksburg, MD, MBA

Hypofractionation for Prostate Cancer

Seth R. Blacksburg, MD, MBA, explains the rationale for hypofractionation for prostate cancer and reviews the modality’s biochemical control, toxicity, and cost-effectiveness through prospective and randomized trials. He also discusses stereotactic body radiation therapy (SBRT) as an alternative treatment option.

Read More

Adjuvant or Salvage RT Post-Radical Prostatectomy

Seth R. Blacksburg, MD, MBA, discusses the clinical significance of biochemical failure post-radical prostatectomy (RP). He then reviews the literature regarding adjuvant and salvage radiation therapy (RT) for prostate cancer biochemical recurrence. Furthermore, he summarizes consensus guidelines, meta level considerations and debates regarding adjuvant and salvage RT, and prospective trials.

Read More

Join the GRU Community

- Why Join? -